You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

CLINICAL TRIALS PROFILE FOR NETUPITANT; PALONOSETRON HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for netupitant; palonosetron hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01339260 ↗ An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed Parexel Phase 3 2011-04-01 NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy.
NCT01339260 ↗ An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed Helsinn Healthcare SA Phase 3 2011-04-01 NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy.
NCT01376297 ↗ A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed Parexel Phase 3 2011-07-01 NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone. The objective of the study is to evaluate if netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
NCT01376297 ↗ A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed Helsinn Healthcare SA Phase 3 2011-07-01 NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone. The objective of the study is to evaluate if netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
NCT02517021 ↗ A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting Completed PSI CRO Phase 3 2015-11-01 NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
NCT02517021 ↗ A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting Completed PSI CRO AG Phase 3 2015-11-01 NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
NCT02517021 ↗ A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting Completed Helsinn Healthcare SA Phase 3 2015-11-01 NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for netupitant; palonosetron hydrochloride

Condition Name

Condition Name for netupitant; palonosetron hydrochloride
Intervention Trials
Chemotherapy-induced Nausea and Vomiting 9
Malignant Neoplasm 2
Adverse Event 1
Malignant Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for netupitant; palonosetron hydrochloride
Intervention Trials
Vomiting 15
Nausea 11
Breast Neoplasms 3
Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for netupitant; palonosetron hydrochloride

Trials by Country

Trials by Country for netupitant; palonosetron hydrochloride
Location Trials
United States 72
Italy 7
Ukraine 4
Serbia 3
Russian Federation 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for netupitant; palonosetron hydrochloride
Location Trials
South Carolina 5
Ohio 5
New York 4
Florida 4
California 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for netupitant; palonosetron hydrochloride

Clinical Trial Phase

Clinical Trial Phase for netupitant; palonosetron hydrochloride
Clinical Trial Phase Trials
Phase 4 1
Phase 3 6
Phase 2/Phase 3 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for netupitant; palonosetron hydrochloride
Clinical Trial Phase Trials
Completed 7
Recruiting 6
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for netupitant; palonosetron hydrochloride

Sponsor Name

Sponsor Name for netupitant; palonosetron hydrochloride
Sponsor Trials
Helsinn Healthcare SA 8
National Cancer Institute (NCI) 3
PSI CRO AG 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for netupitant; palonosetron hydrochloride
Sponsor Trials
Other 19
Industry 13
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.